文献速递肝病

肝脏IRF2BP2通过直接抑制ATF3转录减轻非酒精性脂肪性肝病

Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3.
PubMed 文献 · Hepatology · 2020-01-30

该研究在小鼠中采用功能获得与缺失实验,发现肝细胞特异性敲除Irf2bp2加重高脂饮食诱导的肝脏脂肪变性、胰岛素抵抗和炎症,而过表达则保护小鼠免受这些代谢紊乱。机制上IRF2BP2通过结合ATF3启动子区域负调控其转录,ATF3敲低可缓解IRF2BP2敲除加重的肝脂肪变性。

要点

  • 肝细胞IRF2BP2缺失加重高脂饮食诱导的脂肪变性、胰岛素抵抗和炎症。
  • IRF2BP2过表达可保护小鼠免受上述代谢紊乱。
  • IRF2BP2作为转录抑制因子直接结合ATF3启动子抑制其表达。

核心结论

  • IRF2BP2通过转录抑制ATF3基因表达,综合控制NAFLD中的肝脏脂肪变性、胰岛素抵抗和炎症。

研究设计与样本

  • 在小鼠中采用功能获得与功能缺失方法研究IRF2BP2在NAFLD中的作用。
  • 利用人肝细胞系在体外验证IRF2BP2对肝脂肪变性的抑制作用。
  • 结合数字基因表达分析和染色质免疫沉淀测序鉴定ATF3为IRF2BP2负调控靶点。

主要发现

  • 肝细胞特异性Irf2bp2敲除加重高脂饮食诱导的肝脏脂肪变性、胰岛素抵抗和炎症。
  • 肝脏Irf2bp2过表达保护小鼠免受高脂饮食诱导的上述代谢紊乱。
  • IRF2BP2对肝脂肪变性的抑制作用在人肝细胞系体外实验中保守。
  • 染色质免疫沉淀和荧光素酶实验证实IRF2BP2通过结合ATF3启动子区域直接抑制ATF3基因转录。
  • ATF3敲低在体外显著缓解IRF2BP2敲除加重的肝脂肪变性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Although knowledge regarding the pathogenesis of nonalcoholic fatty liver disease (NAFLD) has profoundly grown in recent decades, the internal restrictive mechanisms remain largely unknown. We have recently reported that the transcription repressor interferon regulatory factor-2 binding protein 2 (IRF2BP2) is enriched in cardiomyocytes and inhibits pathological cardiac hypertrophy in mice. Notably, IRF2BP2 is abundantly expressed in hepatocytes and dramatically down-regulated in steatotic livers, whereas the role of IRF2BP2 in NAFLD is unknown. APPROACH AND RESULTS: Herein, using gain-of-function and loss-of-function approaches in mice, we demonstrated that while hepatocyte-specific Irf2bp2 knockout exacerbated high-fat diet-induced hepatic steatosis, insulin resistance and inflammation, hepatic Irf2bp2 overexpression protected mice from these metabolic disorders. Moreover, the inhibitory role of IRF2BP2 on hepatosteatosis is conserved in a human hepatic cell line in vitro. Combinational analysis of digital gene expression and chromatin immunoprecipitation sequencing identified activating transcription factor 3 (ATF3) to be negatively regulated by IRF2BP2 in NAFLD. Chromatin immunoprecipitation and luciferase assay substantiated the fact that IRF2BP2 is a bona fide transcription repressor of ATF3 gene expression via binding to its promoter region. Functional studies revealed that ATF3 knockdown significantly relieved IRF2BP2 knockout-exaggerated hepatosteatosis in vitro. CONCLUSION: IRF2BP2 is an integrative restrainer in controlling hepatic steatosis, insulin resistance, and inflammation in NAFLD through transcriptionally repressing ATF3 gene expression.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Fang J, Ji YX, Zhang P, et al. Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3. Hepatology. 2020. PMID: 31529495. doi:10.1002/hep.30950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。